Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA

NCT02963727 Phase 1 UNKNOWN

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Details

Lead sponsor	Hanan Jafar
Phase	Phase 1
Status	UNKNOWN
Enrolment	10
Start date	2017-01-27
Completion	2021-12

Conditions

• Knee Osteoarthrosis

Interventions

• Wharton Jelly derived mesenchymal stem cell

Primary outcomes

• Evaluation of the safety and tolerability of the intra articular injection — 6 months
  patients will be monitored for any adverse events resulting from the intraarticular injection of WJMSC

Countries

Jordan